{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Healthy Enterprise","title":"MONEY BALL Episode 1 - James Lovgren, Aspiro Therapeutics","html":"","width":"100%","height":180,"duration":1610,"description":"This episode is part of a limited series called Money Ball in conjunction with the BLPN Club . BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences.\nIn this conversation, James Lovgren shares his insights on the funding process for biotech startups, emphasizing the importance of team expertise, the art of pitching, and the need to balance scientific detail with storytelling. He discusses the iterative nature of pitching, the significance of understanding investor expectations, and the value of targeting the right investors to enhance the chances of success. James reflects on his experiences in the Money Ball program, highlighting the lessons learned and the importance of adaptability in investor conversations.\nChapters:\n00:00 Introduction to Money Ball and Aspiro Therapeutics\n01:13 Understanding Obstructive Lung Diseases\n02:59 Innovative Solutions in Lung Disease Treatment\n05:04 The Journey of Aspiro Therapeutics\n07:05 The Importance of Team Dynamics\n09:09 Mastering the Pitch Process\n10:50 Evolving the Pitch: Lessons Learned\n12:58 Investor Engagement and Feedback\n14:56 Navigating Investor Relationships\n17:09 Refining the Pitch Through Iteration\n19:01 The Role of Investor Fit\n21:07 Future Directions for Aspiro Therapeutics\nGuest Information:Guest's Name: James LovgrenGuest's Title/Position:  CEO & Co-FounderGuest's Linkedin: https://www.linkedin.com/in/jameslovgren/Company / Affiliation: Aspiro Therapeutics https://aspirotx.com/Guest's Bio:  As the CEO of Aspiro Therapeutics, James Lovgren leads the company’s mission to revolutionize the treatment of obstructive lung diseases with innovative CC16-inspired therapies.\nJames is an accomplished life science executive with a distinguished track record of commercializing disruptive technologies and managing global product portfolios exceeding $250 million. His extensive background spans...","thumbnail_url":"https://img.transistorcdn.com/WKku9MQ84q-0q9Awqd5xdS4eoTolo1ocic6_1x8xlF0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMjI4/MDliNWYyM2MxYWFi/NTkwZmIwNzJkYjk2/YjliMy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}